Intravenous iron therapy: well-tolerated, yet not harmless.
about
Plasma vitamin C levels in ESRD patients and occurrence of hypochromic erythrocytes.Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response.Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors.Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated.
P2860
Intravenous iron therapy: well-tolerated, yet not harmless.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Intravenous iron therapy: well-tolerated, yet not harmless.
@ast
Intravenous iron therapy: well-tolerated, yet not harmless.
@en
type
label
Intravenous iron therapy: well-tolerated, yet not harmless.
@ast
Intravenous iron therapy: well-tolerated, yet not harmless.
@en
prefLabel
Intravenous iron therapy: well-tolerated, yet not harmless.
@ast
Intravenous iron therapy: well-tolerated, yet not harmless.
@en
P2093
P2860
P1476
Intravenous iron therapy: well-tolerated, yet not harmless.
@en
P2093
Sengölge G
Sunder-Plassmann G
P2860
P356
10.1111/J.1365-2362.2005.01530.X
P478
35 Suppl 3
P577
2005-12-01T00:00:00Z